SCHEDULE: Affinity Asset Advisors Discloses 9% Stake in Ovid Therapeutics

Affinity Asset Advisors, LLC and Michael Cho have disclosed a 9.0% beneficial ownership stake in Ovid Therapeutics Inc., including shares from warrants.

Summary

• Affinity Asset Advisors, LLC and Michael Cho collectively beneficially own 12,149,166 shares of Ovid Therapeutics Inc. common stock.
• This represents approximately 9.0% of the company's outstanding common stock.
• The ownership includes 4,999,166 shares issuable upon the exercise of warrants held by Affinity Healthcare Fund, LP.
• The percentage is calculated based on 130,184,353 shares outstanding as of December 15, 2025, plus the warrant shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional stake, even if passive, can indicate investor confidence in the company's value or future potential.

Management Comments

• Affinity Asset Advisors, LLC, as investment manager of Affinity Healthcare Fund, LP, exercises voting and investment power over the securities.
• Michael Cho, the managing member of Affinity Asset Advisors, LLC, may be deemed a beneficial owner of the securities.
• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that a 9.0% stake by an investment adviser like Affinity Asset Advisors, LLC, while passive according to the filing, represents a significant institutional position in Ovid Therapeutics Inc., a biotechnology company. Such a substantial holding can signal confidence in the company's long-term prospects within the specialized biotech sector, potentially attracting attention from other institutional investors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 9.0% stake may be viewed positively, potentially increasing market confidence and liquidity.

Key Dates

Keywords

Ovid Therapeutics, Affinity Asset Advisors, Michael Cho, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investor, Biotechnology